A process for preparing a pharmaceutical composition that is stabilised against oxidation, wherein the composition is an emulsion for intravenous administration comprising: 0.5 mg per mL of clevidipine or a pharmaceutically acceptable salt thereof, 20% soybean oil, glycerin, purified egg yolk phospholipids, water, and sodium hydroxide, wherein the process comprises the steps of: (a) dispensing water for injection to a mix tank at 74 °C to 78 °C; (b) adding glycerin to the water and cooling the resulting aqueous phase to 60 °C to 70 °C; (c) dispensing soybean oil into a dissolving tank to form an oil phase; (d) mixing and heating the soybean oil to 70 °C to 82 °C; (e) adding clevidipine to the soybean oil mixture and heating to 78 °C to 82 °C; (f) adding egg yolk phospholipids to the mixture of clevidipine and soybean oil; (g) mixing the aqueous phase and the oil phase to form an emulsion; (h) adjusting the pH with 1N sodium hydroxide to a pH of 6.0 to 8.8; and (i) homogenising the emulsion at a pressure of 500/8000psi at a temperature of 50 °C to 55 °C;, and wherein oxidation of the composition is minimised by reducing the amount of light exposure during the manufacturing and storing processes, such that the amount of H324/78 having the following formula: is less than or equal to about 0.2% on a weight-to-weight basis to clevidipine. 0.5 mg per mL of clevidipine or a pharmaceutically acceptable salt thereof, 20% soybean oil, glycerin, purified egg yolk phospholipids, water, and sodium hydroxide, wherein the process comprises the steps of: (a) dispensing water for injection to a mix tank at 74 °C to 78 °C; (b) adding glycerin to the water and cooling the resulting aqueous phase to 60 °C to 70 °C; (c) dispensing soybean oil into a dissolving tank to form an oil phase; (d) mixing and heating the soybean oil to 70 °C to 82 °C; (e) adding clevidipine to the soybean oil mixture and heating to 78 °C to 82 °C; (f) adding egg yolk phospholipids to the mixture of clevidipine and soybean oil; (g) mixing the aqueous phase and the oil phase to form an emulsion; (h) adjusting the pH with 1N sodium hydroxide to a pH of 6.0 to 8.8; and (i) homogenising the emulsion at a pressure of 500/8000psi at a temperature of 50 °C to 55 °C;, and wherein oxidation of the composition is minimised by reducing the amount of light exposure during the manufacturing and storing processes, such that the amount of H324/78 having the following formula: is less than or equal to about 0.2% on a weight-to-weight basis to clevidipine. (a) dispensing water for injection to a mix tank at 74 °C to 78 °C; (b) adding glycerin to the water and cooling the resulting aqueous phase to 60 °C to 70 °C; (c) dispensing soybean oil into a dissolving tank to form an oil phase; (d) mixing and heating the soybean oil to 70 °C to 82 °C; (e) adding clevidipine to the soybean oil mixture and heating to 78 °C to 82 °C; (f) adding egg yolk phospholipids to the mixture of clevidipine and soybean oil; (g) mixing the aqueous phase and the oil phase to form an emulsion; (h) adjusting the pH with 1N sodium hydroxide to a pH of 6.0 to 8.8; and (i) homogenising the emulsion at a pressure of 500/8000psi at a temperature of 50 °C to 55 °C;, and wherein oxidation of the composition is minimised by reducing the amount of light exposure during the manufacturing and storing processes, such that the amount of H324/78 having the following formula: